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Although dipeptidyl peptidase IV (DPPIV) inhibitors are known to have renoprotective effects, the mechanism underlying
these effects has remained elusive. Here we investigated the effects of DA-1229, a novel DPPIV inhibitor, in two animal
models of renal injury including db/db mice and the adriamycin nephropathy rodent model of chronic renal disease
characterized by podocyte injury. For both models, DA-1229 was administered at 300 mg/kg/day. DPPIV activity in the
kidney was significantly higher in diabetic mice compared with their nondiabetic controls. Although DA-1229 did not
affect glycemic control or insulin resistance, DA-1229 did improve lipid profiles, albuminuria and renal fibrosis. Moreover,
DA-1229 treatment resulted in decreased urinary excretion of nephrin, decreased circulating and kidney DPPIV activity,
and decreased macrophage infiltration in the kidney. In adriamycin-treated mice, DPPIV activity in the kidney and urinary
nephrin loss were both increased, whereas glucagon-like peptide-1 concentrations were unchanged. Moreover, DA-1229
treatment significantly improved proteinuria, renal fibrosis and inflammation associated with decreased urinary nephrin
loss, and kidney DPP4 activity. In cultured podocytes, DA-1229 restored the high glucose/angiotensin II-induced increase
of DPPIV activity and preserved the nephrin levels in podocytes. These findings suggest that activation of DPPIV in the
kidney has a role in the progression of renal disease, and that DA-1229 may exert its renoprotective effects by preventing
podocyte injury.
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Dipeptidyl peptidase IV (DPPIV) inhibition is believed to
exert its antidiabetic effects by enhancing the production of
incretins such as glucose-dependent insulinotropic polypeptide
and glucagon-like peptide-1 (GLP-1), and GLP-1 receptors
have also been found in extra-pancreatic tissues and
incretin-based agents have been shown to have possible
pleiotropic actions beyond glucose control.1–6 Many experimental
and clinical trials have concluded that DPPIV inhibition
decreases albuminuria in DN and can potentially delay the
onset and progression of DN, in addition to improving kidney
function in glycemic controls.7–14
Numerous studies have provided evidence that podocyte
dysfunction, such as podocyte loss, has a central role in the
development and progression of DN.15,16 For example, the
decreased nephrin expression observed in DN has been
associated with increased albuminuria, and recent reports
have also demonstrated that DPPIV expression is upregulated
in the glomeruli of patients with DN.7,17–19 Moreover, DPPIV
inhibition has been shown to delay DN progression by
attenuating podocyte injury via a glucose-independent
mechanism.7 Furthermore, DPPIV inhibition has been shown
to improve proteinuria, podocyte function in an animal
model of obesity-related glomerulopathy.20 Taken together,
these findings indicate that DPPIV inhibition may affect
podocyte function in DN.
However, few reports have evaluated the role of DPPIV on
renal injury, specifically on podocyte injury, in a mouse
model of type 2 diabetes. Thus, here we investigated the
effects of DA-1229, a novel DPPIV inhibitor, on DN in db/db
mice. In addition, we also utilized a mouse model of chronic
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progressive kidney disease characterized by podocyte injury,
adriamycin nephropathy, to examine the effect of DPPIV
inhibition on the progression of renal disease. In addition, to
elucidate the molecular mechanism by which DPPIV acts, we
performed in vitro experiments using cultured podocytes to
evaluate the effects of high glucose and angiotensin II on
DPPIV activity and nephrin levels.
MATERIALS AND METHODS
Animal Studies
Animal studies were conducted in two different mouse
models of disease, type 2 diabetes and adriamycin nephropathy.
For the type 2 diabetes model, six-week-old male
diabetic db/db mice (C57BLKS/J-leprdb/leprdb) and male
nondiabetic db/m mice (C57BLKS/J-leprdb/+) were purchased
from The Jackson Laboratory (Sacramento, CA, USA).
DA-1229 (evogliptin) tartrate, a DPPIV inhibitor, was
obtained from Dong-A ST Research Institute (Yongin,
Republic of Korea). Mice were divided into three experi-
mental groups (n= 8 per group): nondiabetic db/m mice as
nondiabetic controls, untreated db/db mice and drug-treated
db/db mice. Mice were fed with either normal chow or 0.3%
DA-1229-chow admixture (mean administered dose of
297.2± 0.10 mg/kg/day) for 12 weeks from 8 weeks of age.
For the adriamycin model, 10-week-old male BALB/c mice
were administered a single intravenous injection of adriamycin
(doxorubicin hydrochloride; Sigma, St Louis, MO, USA)
at 13 mg/kg. These conditions were chosen based on
preliminary experiments showing that a single tail vein
injection of this dose induced significant proteinuria and
progressive glomerulosclerosis by 3 weeks after injection. For
the adriamycin model, preventive and therapeutic protocols
were performed (n= 7 per group). To analyze the preventive
effects of DA-1229 in adriamycin model, DA-1229 was
administered in mixed chow at a dose of 300 mg/kg/day for
3 weeks beginning with the adriamycin injection. Mice were
then killed 3 weeks after the adriamycin injection. For the
therapeutic protocol, DA-1229 treatment was initiated 3 weeks
after adriamycin injection and the treatment was continued
for 2 weeks. Mice were then killed at 5 weeks post-adriamycin
injection. All mice were provided with a standard diet and
water and were maintained in a temperature-controlled
(23± 2°C) and humidity-controlled (55± 5%) room with a
12-h light/12- h dark cycle. Daily food intake was monitored
at regular intervals to confirm drug administration. During
experiments, food intake, water intake, urine volume, body
weight, fasting blood glucose concentration and HbA1c levels
were measured monthly. Blood glucose levels were measured
using the glucose oxidase-based method and plasma creati-
nine levels were determined by HPLC. Plasma insulin and
adiponectin levels were measured using an ELISA kit (Linco
Research, St Charles, MO, USA). The homeostasis model
assessment index (HOMA-IR) was calculated by the following
equation: fasting glucose (mmol/l) x fasting insulin (mU/l)/
22.5. Plasma triglyceride and cholesterol analyses were
performed using a GPO-Trinder kit (Sigma-Aldrich, St Louis,
MO, USA). Plasma lipoprotein profiles were measured using
a fast protein HPLC system. To determine urinary albumin
excretion, individual mice were caged once each month in a
metabolic cage, and urine was collected for 24 h. Urinary
albumin concentrations were determined by a competitive
ELISA kit (ALPCO, Westlake, OH, USA). Urinary nephrin
concentrations were also determined by an ELISA kit
(Exocell, Philadelphia, PA, USA) and corrected according to
urine creatinine concentrations. Plasma active GLP-1 levels
were determined by an ELISA kit (Millipore, St Charles, MO,
USA). Plasma MCP-1 concentrations were assessed by an
ELISA kit (Abcam Plc, Cambridge, MA, USA). Plasma and
urinary levels of 8-isoprostane were measured using an ELISA
kit (Cayman Chemical, Ann Arbor, MI, USA). At the end of
the study period, systolic blood pressure was measured using
tail-cuff plethysmography with an LE 5001-Pressure Meter
(Letica SA, Barcelona, Spain). Mice were killed under
anesthesia through i.p. injections of sodium pentobarbital
(50 mg/kg). All ELISA analyses were performed in triplicate,
and the results were averaged. All experiments were
conducted in accordance with NIH guidelines and with the
approval of the Korea University Institutional Animal Care
and Use Committee.
DPPIV Activity Assay
DPPIV activity was measured in plasma, cells and tissues as
previously described.21 Briefly, 0–40 μM of AMC (7-amino-4-
methylcoumarin) standard was loaded into each well and read
fluorometrically at Em/Ex= 360/465 nm, generating a linear
standard curve. Next, 50 μl of plasma sample was added to
each of the 96-wells, followed by the addition of 50 μl
substrate solution (final concentrations 0.1 M HEPES, 50 μM
Gly-Pro-AMC and 50 μg/ml BSA) per well. Free AMC, which
was released by DPPIV activity, was quantitated by fluorometric
measurements every 25 s for 300 s using a Spectramax
GEMINI XPS microplate reader (Molecular Devices, Sunnyvale,
CA, USA; Em/Ex= 360/465 nm, target temperature= 25ºC).
To analyze DPPIV activity in renal tissue and cells, frozen
tissue (10 mg) or cells (2 × 106) were homogenized in cold
assay buffer (25 mM Tris-HCl, 140 mM NaCl, 10 mM KCl,
pH 7.5, 0.1% BSA) and spun by centrifugation at 20 000 g for
20 min at 4ºC. DPPIV activity in the lysates was measured as
described above. DPPIV activity in each tissue sample was
expressed as the amount of cleaved AMC per minute per
gram of tissue (μM/min/g tissue).
Histological and Immunohistochemical Analysis
Kidney and hepatic tissue samples were fixed in 4%
paraformaldehyde and embedded in paraffin. Samples were
cut into 4-μm thick slices and stained with periodic acid–Schiff
or hematoxylin and eosin. For immunohistochemical
staining, sections were microwaved for 10–20 min to retrieve
antigens for TGF-β1, nephrin, α-SMA, WT-1 and F4/80
staining. Alternatively, sections were transferred to Biogenex
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Retrievit buffer (pH 8.0) (InnoGenex, San Ramon, CA, USA)
and microwaved for 10–20 min for antigen retrieval for
plasminogen activator inhibitor (PAI)-1 staining, or treated
with trypsin (Sigma) for 30 min at 37 °C to detect type IV
collagen. To block endogenous peroxidase activity, 3.0%
H2O2 in methanol was applied to the tissue sections for
20 min. Samples were then incubated at room temperature
for 60 min in 3% BSA/3% normal goat serum (type IV
collagen, α-SMA, WT-1 and F4/80), 30 min with 5% normal
goat serum (nephrin), 15 min with 10% powerblock (PAI-1)
or 30 min with 20% normal sheep serum (TGF-β1). Slides
were incubated overnight at 4 °C with rabbit polyclonal
anti-TGF-β1 antibodies (1:200; Santa Cruz Biotechnology),
rabbit polyclonal anti-WT-1 antibodies (1:400, Santa Cruz
Biotechnology), mouse monoclonal anti-F4/80 antibodies
(1:100; Serotec, Raleigh, NC, USA), rabbit polyclonal
anti-type IV collagen antibodies (1:150; BioDesign
International, Sarco, ME, USA), guinea pig polyclonal
anti-nephrin antibodies (1:50; PROGEN Biotechnik GmbH,
Heidelberg, Germany), rabbit polyclonal anti-PAI-1
antibodies (1:60; American Diagnostica, Stamford, CT,
USA) or rabbit polyclonal anti-α-SMA antibodies (1:100;
Santa Cruz Biotechnology). After overnight incubation, slides
were incubated with secondary antibodies for 30 min.
Immunoreactive areas were detected by incubation at room
temperature with a mixture of 0.05% 3,3-diaminobenzidine
containing 0.01% H2O2 followed by counterstaining with
Mayer’s hematoxylin. Negative control sections were stained
under identical conditions but with a buffer solution instead
of the primary antibody. Glomerular mesangial expansion in
diabetic mice was scored semiquantitatively as described
previously,22 and the degree of glomerulosclerosis in the
adriamycin nephropathy model was scored according to the
method described by Ma et al.23 Macrophages infiltrating
the interstitium were counted and expressed as the number of
macrophages per high-power field. After α-SMA staining, the
degree of tubulointerstitial fibrosis was assessed by a
point-counting method as described previously.24 To evaluate
the immunohistochemical staining for type IV collagen,
TGF-β1, PAI-1, WT-1 and F4/80, glomerular fields were
graded semiquantitatively under a high-power field containing
50–60 glomeruli and an average score was calculated as
described previously.22 All histologic examinations were
conducted by a trained pathologist in a blinded manner.
Analysis of Gene Expression by Real-Time Quantitative
PCR
Total RNA was extracted from renal cortical tissue samples
and cells with Trizol reagent and further purified using an
RNeasy Mini kit (Qiagen, Valencia, CA, USA). Primers were
designed from respective gene sequences using Primer 3
software and the secondary structures of the templates were
examined and excluded using mfold software. The nucleotide
sequences of all primers used in this study are shown in
Table 1. Real-time quantitative PCR was performed using a
Table 1 Primer sequences for real-time quantitative PCR
Target gene Primer sequence (5' to 3')
GLP-1R, forward GCCCATTCTCTTTGCTATCG
GLP-1R, reverse GCCTTCAGTTTGGAGACCAC
PAI-1, forward TCCTCATCCTGCCTAAGTTCTC
PAI-1, reverse GTGCCGCTCTCGTTTACCTC
TGF-β1, forward AGCCCGAAGCGGACTACTAT
TGF-β1, reverse CTGTGTGAGATGTCTTTGGTTTTC
Col-IV, forward GCTCTGGCTGTGGAAAATGT
Col-IV, reverse CTTGCATCCCGGGAAATC
TLR4, forward GGGAACAAACAGCCTGAGAC
TLR4, reverse AGACCCATGAAATTGGCA T
HMG-CoA, forward AGCCGAAGCAGCACATGAT
HMG-CoA, reverse CTTGTGGAATGCCTTGTGATTG
ABCA1, forward CGTTTCCGGGAAGTGTCCTA
ABCA1, reverse GCTAGAGATGACAAGGAGGATGGA
TNF-α, forward CCGATGGGTTGTACCTTGTC
TNF-α, reverse GGCAGAGAGGAGGTTGACTTT
IL-1β, forward CTCACAAGCAGAGCACAAGC
IL-1β, reverse ACGGATTCCATGGTGAAGTC
MCP-1, forward CTGGATCGGAACCAAATGAG
MCP-1, reverse CGGGTCAACTTCACATTCAA
NOX4, forward ATTTGGATAGGCTCCAGGCAAAC
NOX4, reverse CACATGGGTATAAGCTTTGTGAGCA
IFN-γ, forward GCGTCATTGAATCACACCTG
IFN-γ, reverse TGAGCTCATTGAATGCTTGG
HMGB1, forward AACCTGATGCAGCGAAAAAG
HMGB1, reverse CCTCATCCTCTTCATCCTCCT
Oeteopontin, forward GATGATGATGACGATGGAGACC
Osteopontin, reverse CGACTGTAGGGACGATTGGAG
E-cadherin, forward CAAGGACAGCCTTCTTTTCG
E-cadherin, reverse TGGACTTCAGCGTCACTTTG
FSP-1, forward CCTCTCTACAACCCCTCTCT-
FSP-1, reverse GGACACCATCACATCCAG
α-SMA, forward CTGACAGAGGCACCACTGAA
α-SMA, reverse CATCTCCAGAGTCCAGCACA
β-Actin, forward GGACTCCTATGTGGGTGACG
β-Actin, reverse CTTCTCCATGTCGTCCCAGT
Abbreviations: ABCA1, ATP-binding cassette transporter-1; Col-IV, type IV
collagen; FSP-1, fibroblast-specific protein 1; GLP-1R, glucargon-like peptide-1
receptor; HMGB1, high-mobility group protein B1; HMG-CoA, 3-hydroxy-3-
methylglutaryl (HMG)-CoA reductase; IFN-γ, interferon-gamma; IL-1β,
interleukin-1β; MCP-1, monocyte chemoattractant peptide-1; NOX4, NADPH
oxidase 4; PAI-1, plasminogen activator inhibitor-1; TGF-β, transforming
growth factor-β; TLR4, Toll-like receptor 4; TNF-α, tumor necrosis factor-α. In
this experiment, each sample was run in triplicate, and the corresponding
non-reverse transcribed mRNA samples were used as negative controls. The
mRNA level of each sample was normalized to that of β-actin mRNA.
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LightCycler 1.5 system (Roche Diagnostics, Indianapolis, IN,
USA) using SYBR Green technology. Thermocycling conditions
consisted of 22–30 cycles of denaturation for 10 s at
95 °C followed by annealing and extension for 30 s at 60 °C.
The expression ratio of each gene relative to β-actin (relative
gene expression) was calculated by subtracting the threshold
cycle number (Ct) of the target gene from that of β-actin and
raising 2 to the power of this difference.
Protein Extraction and Western Blot Analysis
Protein extracts were prepared from renal cortical tissue
samples and cells using a standard method, and 40 μg of
protein was electrophoresed on 10% SDS-PAGE minigels,
and the membranes were incubated in blocking buffer
overnight at 4 °C with rabbit polyclonal anti-ATP-binding
cassette transporter-1 antibodies (1:200, Abcam Plc), rabbit
polyclonal anti-TGF-β1 antibodies (1:200; Santa Cruz
Biotechnology), goat polyclonal anti-nephrin antibodies
(1:500, Santa Cruz Biotechnology), goat polyclonal anti-type
I collagen α1 antibodies (1:2000, Abcam Plc), goat polyclonal
anti-3-hydroxy-3-methylglutaryl-coenzyme A (anti-HMG-
CoA) reductase antibodies (1:100, Santa Cruz Biotechnology),
rabbit polyclonal anti-osteopontin antibodies (1:1000, Abcam
Plc), goat polyclonal anti-E-cadherin antibodies (1:500,
Abcam Plc), rabbit polyclonal anti-FSP-1 antibodies (1:200,
Abcam Plc) and mouse monoclonal anti-β-actin antibodies
(1:5000, Sigma-Aldrich). The membranes were subsequently
incubated with horseradish peroxidase-conjugated secondary
antibodies (1:1000 dilution) for 60 min at room temperature.
Immunoreactive bands were detected using enhanced chemi-
luminescence reagents (Amersham, Buckinghamshire, UK).
Immunofluorescence Microscopy for DPPIV
To confirm the presence of DPPIV in cultured podocytes,
immunofluorescence staining was performed for CD26
(DPPIV). Podocytes were grown in a four-chambered glass
slide and then fixed at RT for 10 min in 75% ethanol. The
slides were incubated at 4 °C overnight with rabbit polyclonal
anti-CD26 antibodies (1:500; Abcam Plc) in a solution
containing 0.2% Triton X-100. Nuclei were counterstained
with DAPI. After rinsing in ice-cold PBS, slides were
incubated with fluorescent-labeled (Alexa Fluor 488-conju-
gated) donkey anti-rabbit IgG secondary antibodies (1:200;
Invitrogen, Carlsbad, CA, USA) for 1 h at 37 °C.
In Vitro DPPIV Activity Experiments
The mouse podocyte cell line was obtained from Peter
Mundel at the Albert Einstein College of Medicine, NY, USA.
Figure 1 Time course of DPPIV activity in various organs and effects of DA-1229 on DPPIV activity. (a) DPPIV activity in plasma and various organs over
time. (b) DPPIV activity in the plasma after 3 months of treatment with DA-1229. (c) DPPIV activity in various organs after 3 months of treatment with
DA-1229. Values are expressed as means ± s.e.m. Statistical analysis was performed between different groups at the same time points. *Po0.05,
**Po0.01, ***Po0.001 vs db/m group; #Po0.05, ##Po0.01, ###Po0.001 vs db/db group.
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Cells were cultured in RPMI medium supplemented with
10% FCS. To evaluate the effect of high glucose and
angiotensin II stimulation on DPPIV activity, subconfluent
cells were serum starved for 24 h. Then medium was replaced
with fresh medium containing 30 mM D-glucose and/or
100 nM angiotensin II and cultured for 72 h, and harvested
for measurement of DPPIV activity. To test the effects of
DPPIV activity on macrophage infiltration, cells were treated
Table 2 Physical and biochemical parameters in db/db mice
Parameter Week db/m db/db+vehicle db/db+DA-1229
Body weight (g) 0 24.3 ± 0.5 36.1 ± 1.0* 37.3 ± 0.8*
4 27.4 ± 1.2 47.2 ± 2.0* 49.6 ± 2.5*
8 30.7 ± 0.9 54.9 ± 1.2* 51.4 ± 3.3*
12 33.5 ± 1.1 58.9 ± 2.1* 57.2 ± 2.5*
Daily food intake (g) 0 2.36 ± 0.14 5.44 ± 0.34* 5.31 ± 0.28*
4 3.36 ± 0.04 7.42 ± 0.09* 6.75 ± 0.34*
8 3.90 ± 0.15 7.15 ± 0.09* 6.62 ± 0.15*
12 3.02 ± 0.27 6.01 ± 0.03* 5.67 ± 0.08*
Daily water intake (g) 0 5.5 ± 0.3 12.9 ± 0.6* 10.7 ± 1.4*
4 4.6 ± 0.2 14.8 ± 0.5* 11.6 ± 0.8*
8 4.7 ± 0.1 15.1 ± 0.0* 15.1 ± 0.3*
12 4.1 ± 0.2 16.8 ± 0.4* 8.6 ± 0.4‡,§
Fasting blood glucose (mg/dl) 0 163 ± 15 248 ± 13 12.1 ± 0.9
4 190 ± 11 472 ± 43* 27.3 ± 1.5*
8 168 ± 6 458 ± 22* 23.2 ± 1.9*
12 153 ± 6 562 ± 53* 466± 66§
Urine volume (ml/day) 0 0.30 ± 0.09 0.42 ± 0.07 0.51 ± 0.04*
4 0.23 ± 0.05 1.84 ± 0.28* 1.64 ± 0.34*
8 0.19 ± 0.02 1.04 ± 0.16† 1.30 ± 0.80*
12 0.21 ± 0.02 1.25 ± 0.36‡ 1.07 ± 0.29‡
HbA1c (%) 0 3.32 ± 0.84 6.18 ± 0.19‡ 6.28 ± 0.41‡
4 4.56 ± 0.09 8.90 ± 0.36* 8.72 ± 0.36*
8 4.50 ± 0.18 9.90 ± 0.37* 9.73 ± 0.74*
12 5.14 ± 0.19 9.21 ± 0.43* 8.58 ± 0.79*
Kidney per 100 g BW 12 0.89 ± 0.07 0.82 ± 0.04 0.64 ± 0.08†
Heart per 100 g BW 12 0.44 ± 0.03 0.25 ± 0.09* 0.23 ± 0.09
Fat per 100 g BW 12 2.50 ± 0.29 4.58 ± 0.27* 4.31 ± 0.42*
Liver per 100 g BW 12 3.97 ± 0.09 5.25 ± 0.33† 6.06 ± 0.29
P-adiponectin (μg/ml) 12 16.36 ± 1.24 11.02 ± 1.32‡ 8.38 ± 1.25‡
P-creatinine (μmol/l) 12 35.0 ± 4.0 45.0 ± 6.0 29.0 ± 2.0¶
HOMA-IR 12 0.42 ± 0.20 4.04 ± 1.08‡ 4.45 ± 1.64‡
Active GLP-1 level (pM) 12 10.83 ± 0.26 11.84 ± 0.71 21.12 ± 2.48¶
SBP (mmHg) 12 118 ± 16 115 ± 15 124± 11
P-MCP-1 (pg/ml) 12 12.4 ± 2.3 36.7 ± 3.6* 17.2 ± 2.1¶
P-8-isoprosatne (pg.ml) 12 316 ± 39 978 ± 177† 563± 65§
U-8-isoprostane (ng/mgCr) 12 2.83 ± 0.34 13.27 ± 3.14* 7.65 ± 1.68§
Abbreviations: MCP-1, monocyte chemoattractnet peptide-1; P, plasma.; U, urine. Values are expressed as means ± s.e.m. Statistical analysis was performed
between different groups at the same time points. †Po0.05, ‡Po0.01, *Po0.001 vs db/m control; §Po0.05, ¶Po0.01 vs db/db+vehicle.
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with 30 mM D-glucose and 100 nM of angiotensin II with or
without prior treatment with DA-1229 (10 nM) for 72 h, and
evaluated the relationship between changes of representative
macrophage chemoattractant proteins such as MCP-1 and
osteopontin and DPPIV activity. To test the effects of various
inhibitors on DPPIV activity, cells were cultured in the
presence of 1, 10 and 100 nM of each drug for 72 h. To
determine the effect of inhibiting DPPIV on nephrin
production, DA-1229 (10 nM) was added to cells 60 min
before treatment with high glucose and angiotensin II. All
experiments were performed with three technical replicates.
Cell Viability Assay (3-[4,5-Dimethylthiozol]-2,5-
Diphenyl Tetrazolium Bromide Assay)
A modified colorimetric assay was used to quantify cell
viability. Briefly, confluent cells were cultivated on 96-well
tissue culture plates and made quiescent in serum-deprived
conditions for 24 h. Cells were then incubated for 24, 48 and
72 h in high glucose medium (30 mM D-glucose) with or
without DA-1229 (10 nM). The solubilized formazan product
was then measured in an ELISA at 570 nm.
Statistical Analysis
Nonparametric analysis was performed because of the
relatively small number of samples. Results are expressed
as means± s.e.m. For the adriamycin nephropathy data,
Student’s t-test and the paired t-test were performed to
determine the significance of differences between two groups
and between time points in the same group, respectively. Data
from the db/db mice were analyzed with the Wilcoxon
rank-sum test followed by the Bonferroni correction. The
Kruskal–Wallis test was used to compare 42 groups,
followed by the Mann–Whitney U-test. Correlations between
DPPIV activity levels and supernatant MCP-1 levels were
examined using Spearman's correlation analysis. P-values
o0.05 were considered statistically significant. Statistical
analyses were performed using SPSS for Windows, version
12.0 (SPSS, Chicago, IL, USA).
RESULTS
Kinetics of DPPIV Activity in Diabetic Mice
The levels of DPPIV activity over time in the plasma and
various organs of nondiabetic vs diabetic mice are shown in
Figure 1. DPPIV activity was significantly higher in kidneys
Figure 2 Effects of DA-1229 on plasma lipid concentration, urinary albumin excretion, liver histology and kidney histology. (a) Representative liver
histological findings. (b) Lipid parameters after 3 months of treatment with DA-1229. (c) Effect of DA-1229 on 24- h urinary albumin excretion. (d)
Representative renal histological findings after 3 months of treatment with DA-1229. Values are expressed as means ± s.e.m. Original magnification x400.
Statistical analysis was performed between different groups at the same time points. *Po0.05, ***Po0.001 vs db/m group; #Po0.05, ##Po0.01 vs db/db
group.
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from diabetic mice than nondiabetic mice at the late stage of
disease. However, DPPIV activity in the plasma and other
organs was not significantly different between the two groups
at this stage (Figure 1a). Interestingly, DA-1229 treatment
markedly suppressed DPPIV activity in the plasma and all
organs tested, including the kidney (Figures 1b and c).
Effects of DA-1229 on Physical and Metabolic
Parameters in db/db Mice
The biochemical and physical parameters tested are shown in
Table 2. The mean fasting blood glucose level, HbA1c level,
body weight, urine volume, water and food intake, HOMA-IR,
fat mass per body weight, and liver mass per body weight
were all significantly higher in diabetic db/db mice than
nondiabetic db/m mice. In contrast, the mean plasma level of
adiponectin was significantly lower in diabetic db/db mice.
Interestingly, DA-1229-treated db/db mice showed a
significantly reduced water intake, fasting blood glucose level
and plasma concentration of creatinine compared with
vehicle-treated db/db mice. However, no significant differ-
ences were observed regarding body weight, food intake,
urine volume, tissue weight, HbA1c, HOMA-IR, systolic
blood pressures or plasma adiponectin level between the two
groups. In addition, no significant differences were observed
between the two groups regarding glucose tolerance or insulin
resistance, as determined by the oral GTT and the ITT (data
not shown). Although the levels of active GLP-1 were not
significantly different between diabetic db/db mice and
nondiabetic db/m mice, DA-1229 treatment significantly
increased the level of active GLP-1 in both groups. In addition,
plasma and urinary levels of inflammatory and oxidative
stress markers such as MCP-1 and 8-isoprostane were
significantly increased in diabetic db/db mice than those in
nondiabetic db/m mice. DA-1229 treatment significantly
improved plasma and urinary levels of inflammatory and
oxidative stress markers (Table 2). Interestingly, the
DA-1229-treated group exhibited improved hepatic steatosis
(Figure 2a). In accordance with these changes, the plasma lipid
profiles were significantly improved by DA-1229 treatment as
compared with vehicle-treated db/db mice (Figure 2b).
Effects of DA-1229 Treatment on Kidney Function and
Structure
Throughout the duration of the experiment, urinary albumin
excretion was significantly increased in db/db mice compared
with db/m mice. This increased albuminuria was significantly
attenuated by 8 weeks of DA-1229 treatment, and this
decrease was maintained until 12 weeks of treatment
Figure 3 Effects of DA-1229 on profibrotic and proinflammatory molecules in renal cortical tissue. (a) Glomerular mesangial expansion scores and
immunostaining scores. (b) Effect of DA-1229 on macrophage infiltration. (c) mRNA expression in renal cortical tissue. (d) Representative western blot
showing expression of the GLP-1 receptor, ABCA1 and HMG-CoA reductase in renal cortical tissue. Values are expressed as means ± s.e.m. *Po0.05,
***Po0.001 vs db/m group; #Po0.05, ##Po0.01, ###Po0.001 vs db/db group.
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(Figure 2c). In addition, histological sections of kidneys from
DA-1229 treatment showed significantly attenuated glomer-
ular tuft hypertrophy, mesangial expansion and macrophage
infiltration (Figure 2d). Consistent with these histological
changes, immunohistochemical staining score and the mRNA
expression levels revealed that the levels of profibrotic
markers and macrophage infiltration were significantly
ameliorated by DA-1229 treatment (Figures 3a and c).
However, the renal expression of the GLP-1 receptor was
not significantly different between the two groups (Figure 3d).
Interestingly, the expression of HMG-CoA reductase was
markedly downregulated by DA-1229 treatment. On the other
hand, the expression of adenosine triphosphate-binding
cassette transporter A1 (ABCA1) was significantly upregulated
by DA-1229 treatment (Figures 3c and d).
Effects of DA-1229 on Urinary Excretion of Nephrin and
Podocyte Injury
As shown in Figure 4a, DA-1229 treatment markedly
decreased urinary excretion of nephrin. Moreover, nephrin
expression was markedly downregulated in db/db mice
compared with db/m mice, whereas DA-1229 treatment
restored nephrin expression. Next, we investigated the
expression of DPPIV in untreated (basal state) podocytes by
IF and found that DPPIV exhibited a cytoplasmic distribution
(Figure 4b). To more clearly determine the cause of decreased
urinary excretion of nephrin after DA-1229 treatment, we
next investigated the effect of DA-1229 on podocyte loss by
performing immunostaining with WT-1 and cell viability
assay. As shown in Figure 4c, numbers of WT-1-positive-
stained cells in the glomeruli were significantly increased in
DA-1229 treatment group compared with that in db/db mice
group. In addition, we also observed that DA-1229 pretreatment
significantly increased podocyte survival from high
glucose-induced cytotoxic injury using MTT assay (Figure 4d).
Next, we determined the effect of inhibiting DPPIV on nephrin
synthesis in podocytes. Interestingly, stimulation with high
glucose and angiotensin II markedly reduced the cellular level
of nephrin, whereas treatment with DA-1229 most effectively
restored nephrin production (Figure 4e).
Figure 4 Effects of DA-1229 on urinary excretion of nephrin and cell viability in cultured podocytes. (a) Urinary nephrin excretion after 3 months of
treatment with DA-1229 and representative glomerular immunohistochemical staining for nephrin (original magnification x1000; #Po0.05 vs db/db
group). (b) Representative immunofluorescence staining for CD26 and DAPI staining in cultured podocytes. (c) Representative immunostaining for WT-1
and immunostaining score after 3 months of treatment with DA-1229. (d) Effect of high glucose and DA-1229 on cell viability in cultured podocytes.
(e) Representative western blot showing the effects of various DPPIV inhibitors on nephrin expression. Ang-II, angiotensin II (100 nM); HG, high glucose
(30 mM); NG, normal glucose (5 mM). Values are expressed as means ± s.e.m. *Po0.05, **Po0.01 vs control (NG) or db/m group; #Po0.05, ##Po0.01 vs
HG or db/db group.
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Effects of DA-1229 on DPPIV Activity and
Chemoattractant Protein Synthesis in Cultured
Podocytes
We then evaluated whether high glucose and angiotensin II,
two major mediators of DN, affect DPPIV activity in
podocytes. Although no significant changes in DPPIV activity
were observed after stimulation with high glucose, angiotensin
II significantly increased DPPIV activity and stimulation with
both high glucose and angiotensin II additively increased
DPPIV activity in podocytes (Figure 5a). Regarding the
potencies of the various DPPIV inhibitors, DA-1229 and
saxagliptin were the strongest inhibitors of all drugs tested,
with DA-1229 reducing DPPIV activity by 50% when used at
10 nM (Figure 5b). As DA-1229 significantly decreased
macrophage infiltration in the kidney, we next examined
whether increased DPPIV activity induced upregulation of
chemoattractant proteins such as MCP-1 and osteopontin. As
shown in Figures 5c and e, high glucose and angiotensin II
stimulation markedly increased MCP-1 gene expression and
MCP-1 protein secretion in cultured podocyte. However,
there was no significant change in osteopontin expression
after stimulation with high glucose and angiotensin II.
Furthermore, there was a significant positive correlation
between DPPIV activity and supernatant MCP-1 levels in
cultured podocytes (Figure 5f).
Effects of DA-1229 on DPPIV Activity and Renal Injury in
the Adriamycin Model
As DA-1229 significantly suppressed DPPIV activity and
restored nephrin expression in cultured podocytes, we further
examined the effects of DA-1229 on podocyte injury in
adriamycin mice. Although plasma DPPIV activity was
not significantly different in adriamycin mice compared
with control mice, DPPIV activity in the kidney was signifi-
cantly higher in the adriamycin mice (Figure 6a). In addition,
DA-1229 markedly decreased plasma and renal DPPIV
activity when given both preventively and therapeutically to
adriamycin mice (Figures 6b and c). However, no signifi-
cant differences in the levels of active GLP-1 were observed
among the groups (Figure 6d). In addition, urinary excretion
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of nephrin was markedly decreased in both the preven-
tive and therapeutic groups of adriamycin mice (Figures 6e
and f).
Effects of DA-1229 on Plasma and Urinary Inflammatory
Molecules in Adriamycin Mice
As DPP4 inhibitor has shown to decrease proinflammatory
cytokines and atherosclerotic process in both diabetic patients
and animal models of diabetes independent of the effects on
the glycemic controls, we also measured plasma and urinary
levels of inflammatory and oxidative stress markers such as
MCP-1 and 8-isoprostane in adriamycin model. Similar to the
results in diabetic mice, DA-1229 treatment significantly
decreased plasma and urinary levels of inflammatory and
oxidative stress markers (Figure 7).
Effects of DA-1229 on Renal Structural and Functional
Changes in Adriamycin Mice
The renal pathology and immunostaining of F4/80, α-SMA
and nephrin in DA-1229-treated and -untreated mice are
shown in Figure 8a. PAS and α-SMA immunostaining
revealed extensive glomerulosclerosis, interstitial fibrosis and
tubular atrophy in untreated adriamycin mice. Interestingly,
both the preventative and therapeutic groups of DA-1229-treated
mice significantly decreased macrophage infiltration
(Figures 8a and c). In addition, numbers of WT-1-positive-
stained cells in the glomeruli were significantly increased in
DA-1229 treatment group compared with that in adriamycin
group (Figure 8b). In accordance with the morphological
alterations observed in the kidneys of adriamycin mice,
the renal mRNA expression levels of proinflammatory
and profibrotic cytokines were remarkably decreased with
DA-1229 treatment (Figures 8d and e). In accordance with
these changes, DA-1229-treated mice abolished glomerulo-
sclerosis and interstitial fibrosis in both the preventative and
therapeutic groups (Figures 9a and b). Proteinuria and
albuminuria persistently increased after adriamycin administra-
tion, whereas both preventive and therapeutic DA-1229
treatment significantly prevented adriamycin-induced
changes (Figures 9c and f). In agreement with these
observations, the renal expression of fibrotic proteins such
as type I collagen and TGF-β1 was markedly downregulated
by both preventive and therapeutic treatment with DA-1229
(Figure 9g). As DA-1229 treatment markedly suppressed
fibrotic process in the kidney, we next observed whether
DA-1229 may contribute to the process of epithelial–
mesenchymal transition (EMT). However, we did not find
any significant changes in the representative markers of EMT
Figure 6 Effects of DA-1229 on DPPIV activity in the plasma and kidneys and urinary excretion of nephrin in the adriamycin-induced nephrotoxicity
model. (a) DPPIV activity in the plasma and kidneys. (b) Effects of preventive and therapeutic DA-1229 on plasma DPPIV activity. (c) Effects of DA-1229
on renal DPPIV activity. (d) Concentrations of active GLP-1. (e, f) Urinary excretion of nephrin in the model of adriamycin-induced nephrotoxicity. Values
are expressed as means ± s.e.m. *Po0.05 vs normal mice group; #Po0.05, ###Po0.001 vs adriamycin group.
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such as loss of E-cadherin and gain of FSP1 and α-SMA
(Supplementary Figure 1).
DISCUSSION
In this study, we demonstrated that a novel DPPIV inhibitor,
DA-1229, exhibits renoprotective effects. These effects include
significantly decreasing urinary albumin excretion, improving
renal histological changes and lipid metabolism, and reducing
macrophage infiltration in the kidney. Of particular note, we
also found that DA-1229-mediated inhibition of DPPIV
restored nephrin expression in podocytes and decreased
podocyte injury in both db/db and adriamycin mice.
DA-1229 is currently in late-stage development for the
treatment of type 2 diabetes. This molecule is a reversible and
competitive inhibitor of DPPIV, with an inhibitory activity
almost 6000-fold more selective for human DPP4 compared
with human DPP8 or DPP9.25 In streptozotocin-induced
diabetic mice, DA-1229 has been shown to significantly
reduce plasma DPPIV activity, enhance glucagon-like
peptide-1 levels and improve insulin tolerance.26 In high-fat
diet-induced obese mice, long-term treatment with DA-1229
resulted in significantly improved glucose intolerance and
insulin resistance.27 In a phase I study performed in 72
healthy Korean male volunteers, each of whom received a
single administration of DA-1229 ranging from 1.25 to 60 mg,
DPPIV inhibition was found to be dose dependent, with
groups receiving ≥ 10 mg exhibiting480% DPPIV inhibition
for 424 h.28
In this study, we first observed DPPIV activity in the
plasma and various target organs over time in diabetic mice.
DPPIV activity was not significantly different in the plasma,
hepatic tissue, cardiac tissue or adipose tissue of diabetic mice
compared with control mice. However, DPPIV activity
was significantly higher in the kidneys of diabetic mice
compared with their nondiabetic controls. These results are
consistent with recent reports that DPPIV expression is
upregulated in human renal glomerular epithelial cells during
inflammation29 and in a rat model of type 2 diabetes
mellitus,30 which may suggest a role for DPPIV in the
development of diabetic kidney disease. However, DPPIV
activities in the plasma and all other target organs of diabetic
mice were markedly reduced by DA-1229 treatment, with
reductions of 70–80% in the plasma and kidneys. These
results imply that the administered DA-1229 was successfully
delivered to all organs and that it also systematically
controlled DPPIV activity in diabetic mice. As expected,
Figure 7 Effects of DA-1229 on inflammatory molecules in the plasma and urinary excretion of 8-isoprostane in the adriamycin-induced nephrotoxicity
model. (a) Plasma levels of MCP-1 in experimental animals. (b) Plasma levels of 8-isoprostane in experimental animals. (c) Urinary excretion of 8-
isoprostane in experimental animals. Values are expressed as means ± s.e.m. *Po0.05, **Po0.01 vs adriamycin group.
DPPIV inhibition and podocyte injury
J Eun Lee et al
www.laboratoryinvestigation.org | Laboratory Investigation | Volume 96 May 2016 557
the plasma levels of active GLP-1 were significantly increased
after DA-1229 treatment. However, these levels were not
significantly different between diabetic db/db mice and
nondiabetic db/m mice.
In this study, we observed that DA-1229 improved
dyslipidemia without affecting the serum fasting blood
glucose level or the amount of food intake. Although no
differences were observed regarding the proportions of fat
and liver weight, these findings are in agreement with a
previous study showing that the liver expression of DPPIV
correlates with the histopathologic grades of nonalcoholic
steatohepatitis and hepatosteatosis.31
The most important finding in this study is that DA-1229
mitigates the urinary excretion of albumin and mesangial
expansion in renal tissue. Moreover, these effects are
accompanied by the suppression of profibrotic and
proinflammatory molecule synthesis. In support of the role
of DPPIV inhibition in the inflammatory process, Nistala
et al32 recently reported that DPPIV inhibition prevents
glomerular and tubular injury through reduction in renal
oxidative stress and inflammation in high-fat diet-induced
mice independent of blood pressure and insulin sensitivity.
Interestingly, we also found that DA-1229 improved renal
lipid metabolism in the diabetic kidney. DA-1229 treatment
markedly suppressed the expression of genes involved in
cholesterol synthesis, such as HMG-CoA reductase. On the
other hand, ABCA1, which modulates cholesterol efflux, was
significantly upregulated by DA-1229 treatment.
Furthermore, here we observed for the first time that
podocyte DPPIV activity increases in response to stimulation
with high glucose and angiotensin II. In addition, nephrin
expression was markedly downregulated in the glomeruli of
db/db mice compared with control db/m mice. Interestingly,
DA-1229 treatment also increased nephrin expression in the
glomeruli of diabetic mice. We also observed that numbers of
WT-1-positive-stained cells in the glomeruli were significantly
increased in DA-1229 treatment group compared with that in
db/db mice group. In addition, we observed that DA-1229
pretreatment significantly increased podocyte survival from
high glucose-induced cytotoxic injury using MTT assay.
These findings are in agreement with a recent study showing
that the DPPIV inhibition prevents podocyte loss associated
Figure 8 Effects of DA-1229 on renal structural changes in the adriamycin-induced nephrotoxicity model. (a) Effects of DA-1229 on renal histological
changes. (b) Representative immunostaining for WT-1 and immunostaining score (**Po0.01, ***Po0.001 vs adriamycin group). (c) Effects of DA-1229 on
macrophage infiltration. (d, e) mRNA expression in renal cortical tissue in adriamycin-induced nephrotoxicity. Values are expressed as means ± s.e.m.
Original magnification x400 (PAS, F4/80, α-SMA, WT-1), x1000 (nephrin). *Po0.05, **Po0.01, ***Po0.001 vs adriamycin group; ###Po0.001 vs adriamycin
group at 3 weeks.
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with the suppression of oxidative damage.33 Taken together,
these results suggest that activated DPPIV may induce
podocyte dysfunction, such as podocyte loss, which is
accompanied by increased albuminuria. Another interesting
finding was that various DPPIV inhibitors could differentially
affect DPPIV activity and nephrin restoration. We found that
DA-1229 and saxagliptin were the most potent inhibitors of
DPPIV activity in podocytes, with DA-1229 showing the most
potent effect on nephrin preservation in podocytes.
Recent studies have used animal models to investigate the
possible beneficial effects of the DPPIV inhibitors sitagliptin,
vildagliptin and linagliptin in diabetic nephropathy.13,14,34
These studies found that DPPIV inhibition led to reduced
albuminuria and histological damage; these effects were
associated with anti-inflammatory and antioxidant properties.
However, it is difficult to determine whether the renal effects
of DPPIV inhibitors are independent of their glucose-lowering
effects. Therefore, in this study, we investigated the effects of
DPPIV inhibition in adriamycin nephropathy model to rule out
any indirect effects from blood sugar changes.35
Adriamycin-induced nephropathy is characterized by
podocyte injury followed by glomerulosclerosis, tubulointer-
stitial inflammation and fibrosis.36 Interestingly, DPPIV
activity in the kidney was significantly increased in adriamycin
mice compared with control mice, whereas no significant
differences were observed between the two groups regarding
the plasma level of active GLP-1. Surprisingly, we found that
DA-1229 significantly reduced albuminuria and proteinuria;
improved the expression of inflammatory and fibrosis-related
molecules, and decreased macrophage infiltration. To further
support the role of DPPIV activity in macrophage infiltration,
we also demonstrated that high glucose and angiotensin II
stimulation markedly increased MCP-1 gene expression and
MCP-1 protein secretion as well as increased DPPIV activity,
and there was a significant positive correlation between
DPPIV activity and supernatant MCP-1 levels in cultured
podocytes. Moreover, DA-1229 treatment significantly
prevented the urinary loss of nephrin in adriamycin mice
and in db/db mice. Nephrin is a crucial protein for
maintaining the integrity of the slit diaphragm and nephrin
excretion has been proposed to be an early indicator of
podocyte injury, even before the onset of albuminuria.36,37
Collectively, these findings suggest that the renoprotective
effects of DA-1229 are due to the suppression of DPPIV
activity independent of the glucose-lowering effect and
mediated by the prevention of podocyte injury.
Figure 9 Effects of DA-1229 on urinary protein and albumin excretion in the adriamycin-induced nephrotoxicity model. (a, b) Effects of DA-1229 on
glomerulosclerosis and tubulointerstitial fibrosis (*Po0.05, ***Po0.001 vs adriamycin group; ###Po0.001 vs adriamycin group at 3 weeks). (c, d) Effects
of DA-1229 on proteinuria and albuminuria in the preventive model of adriamycin-induced nephrotoxicity. (e, f) Effects of DA-1229 on proteinuria and
albuminuria in the therapeutic model of adriamycin-induced nephrotoxicity. (g) Representative western blot showing the effects of DA-1229 on type I
collagen and TGF-β1 expression in renal cortical tissue. TGF-β1, transforming growth factor 1. For c–f, Student’s t-test and the paired t-test were
performed to compare two different groups at the same time point and responses within a single group at different time points, respectively. Values
are expressed as means ± s.e.m. Statistical analysis was performed between groups at the same time points. ***Po0.001 vs adriamycin (ADX) group at
0 week; ##Po0.01, ###Po0.001 vs adriamycin (ADX) group.
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Our study differs from previous work, in that we directly
determined DPPIV activity in the kidney, rather than simply
measuring DPPIV expression. We showed that DPPIV activity
was increased in the kidneys of diabetic mice and adriamycin
nephropathy mice, and that DA-1229 treatment suppressed
DPPIV activity, and that DA-1229 treatment resulted in
improved renal function via podocyte protection.
In conclusion, our data suggest that DPPIV inhibitors may
prevent renal disease progression in diabetic and nondiabetic
kidney disease. These findings suggest that DA-1229
treatment is a promising novel strategy for targeting diabetic
nephropathy, in addition to various other glomerular diseases
affecting podocytes.
Supplementary Information accompanies the paper on the Laboratory
Investigation website (http://www.laboratoryinvestigation.org)
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